VIVA aims to determine the feasibility of a study evaluating whether people with spine fractures would benefit from education and training on pain management, nutrition, safe movement, and exercise. Vertebral fractures due to osteoporosis can cause pain and disability. Most people will be offered medications for osteoporosis and for pain, if applicable, but there is no standard rehabilitation for people with spine fractures. The VIVA study tests whether enough participants will join and complete a study examining the effectiveness of an intervention involving pain management, nutrition, safe movement, and exercise, and to understand their experience with the VIVA intervention.

This clinical trial aims to look at how well ianalumab works in participants with renal manifestations in systemic lupus erythematosus, also called lupus nephritis. This study will demonstrate the clinical efficacy of ianalumab administered as a subcutaneous injection monthly or quarterly, compared to matching subcutaneous placebo monthly in adolescent and adult participants with systemic lupus erythematosus, who are on standard-of-care treatment.

This clinical trial aims to look at how well ianalumab works in participants with systemic lupus erythematosus. This study will demonstrate the clinical efficacy of ianalumab administered as a subcutaneous injection monthly or quarterly, compared to matching subcutaneous placebo monthly in adolescent and adult participants with systemic lupus erythematosus, who are on standard-of-care treatment.

Physical activity is an important part of self-management for rheumatoid arthritis. Even though there are positive benefits of physical activity, people with rheumatoid arthritis face many challenges to becoming and staying physically active. Often, there is also not enough support for physical activity from rheumatology healthcare providers. This study aims to learn from rheumatology healthcare providers to identify key opportunities and challenges for supporting physical activity among their patients, with the overall aim of increasing the physical activity levels of people with rheumatoid arthritis.

The INTACT study aims to define the risk of retinal toxicity in patients with rheumatoid arthritis or systemic lupus erythematosus who have been using hydroxychloroquine (also known as Plaquenil) for five or more years. This risk is not well-defined in the literature – it currently stands between 0.5-5%. Participants will receive state-of-the-art retinal toxicity monitoring over five years, at no additional charge to them.